logo

For the Inventor, By the Inventor

Yamaguchi, Japan

Yamaguchi University


USPTO Granted Patents = 89

% Expired Patents = 40.4



Forward Citations = 137

Loading Chart...
Loading Chart...

151 inventors (with patents filed for the assignee):

goldMedal Koji Tamada (9 out of 23 patents)

silverMedal Yukimi Sakoda (8 out of 8 patents)

bronzeMedal Kazuhiro Kimura (8 out of 8 patents)

4.  Yuichi Sakanishi (7 out of 22 patents)

5.  Takashi Saeki (7 out of 7 patents)

6.  Rinji Akada (7 out of 8 patents)

7.  Mitsuru Higa (6 out of 6 patents)

8.  Ryouichi Tsunedomi (5 out of 5 patents)

9.  Keishi Adachi (5 out of 5 patents)

10.  Masaaki Oka (5 out of 15 patents)

11.  Mami Itoh (5 out of 5 patents)

12.  Hisashi Hoshida (5 out of 6 patents)

13.  Atsushi Sanada (5 out of 8 patents)

14.  Shoichi Hazama (4 out of 11 patents)

15.  Atsushi Jikihara (4 out of 11 patents)


Core Competencies:
D-Mannose Isomerase
Glioma Treatment
Immune Function
Gene Transfer
Retinochoroidal Disorders
X-ray Imaging
Cation Exchange Membrane
Thickening Stabilizer
Therapeutic Agents
Ethanol Production
Thin Film Deposition
Stem Cell Activity

89 patents:

1. 12753395 - Cell culture method and cell culture device used with cell culture method (2026-10-06),
2. 12612613 - D-mannose isomerase and production method of D-fructose (2026-04-28),
3. 12594294 - THERAPEUTIC AND PROPHYLACTIC AGENT FOR GLIOMA, BRAIN TUMOR MALIGNANCY MARKER, BRAIN TUMOR PROGNOSTIC MARKER, METHOD FOR DETERMINING MALIGNANCY AND PROGNOSIS OF BRAIN TUMOR AND ANTIBODY INHIBITING TUMOR PROLIFERATION (2026-04-07),
4. 12492950 - Estimation method of stress and strain history in cement-based composite materials and calcite particle aggregates (2025-12-09),
5. 12357613 - Inhibitor for retinochoroidal disorders (2025-07-15),
6. 12129291 - Anti-GPC3 antibody (2024-10-29),
7. 11931381 - Immunocompetent cell and expression vector expressing regulatory factors of immune function (2024-03-19),
8. 11730718 - Inhibitor for retinochoroidal disorders (2023-08-22),
9. 11718663 - Anti-GPC3 antibody (2023-08-08),
10. 11692216 - Method for assisting prediction of risk of occurrence of side effect of irinotecan (2023-07-04),
11. 11670398 - Method for determining pharmacokinetics of axitinib and method for predicting therapeutic effect of axitinib based on pharmacokinetics of axitinib (2023-06-06),
12. 11655298 - Composition for treating fulminant acute pneumonia including CD69 antagonist (2023-05-23),
13. 11617765 - Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cells (2023-04-04),
14. 11471440 - Therapeutic agent for keratoconjunctive disorders (2022-10-18),
15. 11461598 - Information processing device, information processing program, and information processing method (2022-10-04),
Company Overview
Yamaguchi University, located in Yamaguchi, Japan, is a prominent institution focused on advancing biomedical innovations. The university specializes in a range of core technology topics, including D-Mannose Isomerase, glioma treatment, and immune function enhancement. Its research extends to gene transfer techniques, retinochoroidal disorders, and advanced imaging methods such as X-ray imaging. Yamaguchi University is committed to fostering scientific advancements that address critical health challenges and improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

89 Patents

#4 in Yamaguchi

#1,211 in Japan

#8,620 in the World

Yamaguchi, JP
Yamaguchi, Japan

Yamaguchi University

Forward Citations = 137

151 inventors:

goldMedal Koji Tamada (9 out of 23 patents)

silverMedal Yukimi Sakoda (8 out of 8 patents)

bronzeMedal Kazuhiro Kimura (8 out of 8 patents)

4.  Yuichi Sakanishi (7 out of 22 patents)

5.  Takashi Saeki (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Yamaguchi University. Retrieved from https://idiyas.com/company/yamaguchi-university

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…